Azithromycin (N = 147) | Placebo (N = 154) | |
---|---|---|
Demographics | ||
Age – years | 66 ± 9 | 67 ± 10 |
Female sex – no. (%) | 66 (45) | 66 (43) |
BMI – kg/m2 | 24.5 ± 5.9 | 25.1 ± 6.5 |
Comorbidity | ||
Charlson comorbidity index | 4 [3–5] | 4 [3–5] |
Lung disease | ||
mMRC dyspnea score | 4 [2–4] | 4 [2–4] |
Pre-bronchodilator FEV1 – L | 0.90 [0.69–1.23] | 0.95 [0.71–1.36] |
Pre-bronchodilator FEV1 – % pred. | 36.0 [26.3–53.8] | 38.5 [29.0–52.0] |
Pre-bronchodilator FEV1/FVC – % | 40.3 [33.6–48.0] | 45.0 [37.0–52.8] |
GOLD stage – no. (%)a | ||
A | 0 (0) | 1 (1) |
B | 26 (18) | 30 (20) |
C | 1 (1) | 2 (1) |
D | 120 (82) | 121 (79) |
Current smoker – no. (%) | 63 (43) | 65 (42) |
Smoking history – pack-years | 44 [37–50] | 43 [35–50] |
Inhaled therapy for COPD – no. (%) | ||
LABA | 136 (93) | 145 (94) |
LAMA | 118 (80) | 123 (80) |
Inhaled corticosteroids | 118 (80) | 123 (80) |
SABA | 108 (73) | 109 (71) |
Admission presentation | ||
GP intervention prior to admission – no. (%) | ||
Systemic corticosteroids | 48 (33) | 37 (24) |
Antibiotics | 50 (34) | 54 (35) |
Laboratory | ||
C-reactive protein (mg/L) | 14.2 [3.5–61.4] | 21.6 [4.5–59.6] |
Leucocytes (× 109/L) | 10.95 [9.00–13.89] | 9.90 [8.20–13.70] |
Neutrophils (×109/L) | 8.20 [6.00–11.20] | 7.70 [5.60–11.20] |
Eosinophils (× 109/L) | 0.06 [0.00–0.20] | 0.07 [0.00–0.20] |
Standardized acute treatment | ||
Received – no. (%) | 134 (91) | 141 (92) |
Received antibiotic – no. (%) | 145 (99) | 152 (99) |
Pathogen susceptible to antibiotic b − no. (%) | 136 (94) | 144 (95) |